Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$32.14|
|52 Week High||US$18.72|
|52 Week Low||US$94.17|
|1 Month Change||5.21%|
|3 Month Change||34.99%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||5.93%|
Recent News & Updates
|AVIR||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how AVIR performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AVIR performed against the US Market.
Stable Share Price: AVIR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: AVIR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus.
Atea Pharmaceuticals Fundamentals Summary
|AVIR fundamental statistics|
Is AVIR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVIR income statement (TTM)|
|Cost of Revenue||US$93.82m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.43|
|Net Profit Margin||20.16%|
How did AVIR perform over the long term?See historical performance and comparison
Is Atea Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVIR ($32.14) is trading below our estimate of fair value ($510.23)
Significantly Below Fair Value: AVIR is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVIR is poor value based on its PE Ratio (75.4x) compared to the US Pharmaceuticals industry average (22.2x).
PE vs Market: AVIR is poor value based on its PE Ratio (75.4x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: AVIR is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: AVIR is overvalued based on its PB Ratio (4.4x) compared to the US Pharmaceuticals industry average (3.2x).
How is Atea Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVIR's forecast earnings growth (58.4% per year) is above the savings rate (2%).
Earnings vs Market: AVIR's earnings (58.4% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AVIR's revenue (44.8% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: AVIR's revenue (44.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVIR's Return on Equity is forecast to be very high in 3 years time (62.8%).
How has Atea Pharmaceuticals performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
Earnings and Revenue History
Quality Earnings: AVIR has high quality earnings.
Growing Profit Margin: AVIR became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AVIR has become profitable over the past 5 years.
Accelerating Growth: AVIR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AVIR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: AVIR's Return on Equity (5.9%) is considered low.
How is Atea Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AVIR's short term assets ($871.1M) exceed its short term liabilities ($273.7M).
Long Term Liabilities: AVIR's short term assets ($871.1M) exceed its long term liabilities ($29.0K).
Debt to Equity History and Analysis
Debt Level: AVIR is debt free.
Reducing Debt: AVIR has not had any debt for past 5 years.
Debt Coverage: AVIR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AVIR has no debt, therefore coverage of interest payments is not a concern.
What is Atea Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVIR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVIR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Pierre Sommadossi (65 yo)
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
CEO Compensation Analysis
Compensation vs Market: Jean-Pierre's total compensation ($USD2.89M) is below average for companies of similar size in the US market ($USD5.25M).
Compensation vs Earnings: Jean-Pierre's compensation has been consistent with company performance over the past year.
Experienced Management: AVIR's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: AVIR's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: AVIR only recently listed within the past 12 months.
Atea Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Atea Pharmaceuticals, Inc.
- Ticker: AVIR
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.660b
- Shares outstanding: 82.78m
- Website: https://ateapharma.com
Number of Employees
- Atea Pharmaceuticals, Inc.
- 125 Summer Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 02:24|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.